PIA
CRVS icon

Piedmont Investment Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Piedmont Investment Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-241
Closed -$3K – 1321
2018
Q2 		$3K Buy
+241
New +$2.69K ﹤0.01% 2362

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Piedmont Investment Advisors's CRVS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q3 2018, closing a stake of 241 shares — an estimated $3K sold.

Piedmont Investment Advisors first reported a position in CRVS in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 61 funds tracked by Wall St. Rank hold CRVS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Corvus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 241 Corvus Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Piedmont Investment Advisors first reported a position in Corvus Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Corvus Pharmaceuticals position peaked at $3K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.